BACE1 and Alzheimer disease: In unconventional symptomatic AD, the transient suppression of the neuronal integrated stress response implemented concurrently with the long-term administration of the BACE1- and/or BACE2-activating drugs could be sufficient to stop the progression of the disease and to prevent its recurrence within the remaining lifetime of the treated patient.